Literature DB >> 22434654

Varicella zoster virus infection in inflammatory bowel disease.

Garret Cullen1, Rachel P Baden, Adam S Cheifetz.   

Abstract

BACKGROUND: The risk of viral infection is increased in immunosuppressed inflammatory bowel disease (IBD) patients. Varicella zoster virus (VZV) is of particular interest in IBD because of a number of reports of severe, disseminated, and occasionally fatal varicella infection in immunosuppressed IBD patients.
METHODS: We reviewed publications describing VZV infection in IBD patients and combined these data with a review of the current literature relating to both primary and secondary varicella in IBD.
RESULTS: Twenty cases of primary varicella infection and 32 cases of herpes zoster infection have been reported in IBD. Additional cases are reported in clinical trials. The risk of VZV infection is increased with all immunosuppressants used in IBD, but corticosteroids and combination immunosuppression appear to be a particular risk.
CONCLUSIONS: Healthcare providers need to be aware of the various manifestations of primary and secondary VZV infection in immunosuppressed IBD patients. Patients should be screened for VZV immunity and vaccinated prior to commencing immunosuppression.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434654     DOI: 10.1002/ibd.22950

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  23 in total

1.  Vaccination of Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic.

Authors:  Sheena Crosby; Michael J Schuh; Freddy Caldera; Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-01

Review 2.  Oral pathology in inflammatory bowel disease.

Authors:  Miranda Muhvić-Urek; Marija Tomac-Stojmenović; Brankica Mijandrušić-Sinčić
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression.

Authors:  Seper Dezfoli; Gil Y Melmed
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-08

Review 4.  ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Authors:  Francis A Farraye; Gil Y Melmed; Gary R Lichtenstein; Sunanda V Kane
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

Review 5.  Varicella zoster virus infection in patients with inflammatory bowel disease.

Authors:  Maggie Ham; Garret Cullen; Adam S Cheifetz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-01

Review 6.  Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.

Authors:  H Matthew Cohn; Maneesh Dave; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

Review 7.  Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.

Authors:  Christopher Ma; Brennan Walters; Richard N Fedorak
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

Review 8.  A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population.

Authors:  David Kim; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

9.  Severe perianal shingles during azathioprine and budesonide treatment for Crohn's disease-preventable with zoster vaccine?

Authors:  Timothy Ross Elliott; Charles Miller; Finlay A Macrae
Journal:  BMJ Case Rep       Date:  2016-07-20

10.  [Guidelines for vaccination of immunocompromised individuals].

Authors:  Ursula Wiedermann; Harald H Sitte; Heinz Burgmann; Alexander Eser; Petra Falb; Heidemarie Holzmann; Maria Kitchen; Marcus Köller; Herwig Kollaritsch; Michael Kundi; Hans Lassmann; Ingomar Mutz; Winfried F Pickl; Elisabeth Riedl; Maria Sibilia; Florian Thalhammer; Barbara Tucek; Werner Zenz; Karl Zwiauer
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.